Endocrine Abstracts

IntroductionAromatase Inhibitors (AI) are standard therapy for hormone receptor positive breast cancers in post-menopausal patients. Unfortunately, resistance is common and previous studies from our lab suggest that the altered steroid environment may be a driver. Using label-free mass spectrometry we set out to explore the unique androgen receptor (AR) interactome that supervenes in AI resistant breast cancer and associated hyper-androgenic environment....

Introduction: Although breast cancer (BC) is considered a treatable disease, >30% of patients with hormone receptor positive tumours will suffer recurrence post endocrine therapy. One of the fundamental features of cancer cells is their ability to modulate cell metabolism to facilitate survival, stress response, and proliferation. Increasing evidence suggests that these mechanisms play key roles in the development of treatment resistance. Recent publicatio...